Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced hair regrowth using a topical solution containing 5% minoxidil and 0.1% finasteride, despite an initial shedding phase. They reported no side effects and noted significant improvement in hair density, particularly around the crown area.

The user started using Dutasteride 0.5mg, Minoxidil 2.5mg, and Biotin 10mg for hair loss. They are experiencing increased hair thinning, likely due to the shedding phase.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The user experienced hair regrowth after 5 months on 5 mg oral minoxidil and 1 mg dutasteride, following a year of ineffective finasteride use. They noticed progress after an initial shedding phase and hope for further improvement, with expectations of near-max regrowth around 18 months.

The user had a hair transplant in December 2024 and started using topical minoxidil and finasteride in March 2025, along with dermarolling and multivitamins. They are experiencing increased hair shedding and are questioning if it's the "dread shed" phase.

The conversation discusses using a custom topical from Skin Medicinals containing latanoprost for hair loss, which helps move hairs into the anagen phase. The user is curious about the cost and effectiveness of this treatment.

The user is experiencing hair loss and is using 2% ketoconazole shampoo, Minoxidil, and Finasteride. They are considering switching from Finasteride to Dutasteride, but others suggest waiting due to a possible shedding phase.

The user has been using minoxidil and finasteride for almost a year, experiencing initial shedding, followed by regrowth, and then another shedding phase. They are concerned about the effectiveness of their current regimen and are considering adjusting their finasteride dosage.

A 28-year-old male has been using finasteride for 3 years to stabilize hair loss but is now experiencing increased hair shedding and considering switching to dutasteride. Some users suggest it might be a temporary shedding phase, while others discuss potential effects of other factors like creatine.

The user experienced significant hair regrowth using a combination of minoxidil, finasteride (later switching to dutasteride), and tretinoin over two years. They noticed regrowth almost immediately, with no major initial shedding phase, and reported recession and diffuse hair loss patterns.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

The user is experiencing increased hair loss 9 months into a treatment with topical finasteride and minoxidil, along with supplements, and is questioning if this is a temporary phase or if the treatment is ineffective. Opinions vary, with some suggesting shedding is normal, while others debate the effectiveness of topical treatments and the impact of supplements.

The user experienced significant hair regrowth and healthier hair after two months of using oral finasteride, minoxidil, and biotin, despite an initial shedding phase. They reported no negative effects on their beard or facial bloating and were surprised by the quick results.

The user experienced increased hair shedding after one month on 0.25 mg finasteride, despite initial improvement. This shedding may be a normal phase in the hair cycle and could improve in the coming months.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

The user experienced significant hair regrowth after using finasteride, minoxidil, and derma stamping, despite an initial heavy shedding phase. They also take omega-3, zinc, biotin, and folic acid daily, and report improved confidence and hair strength.

The user shares progress on hair regrowth using topical Minoxidil twice daily, tretinoin at night, and oral finasteride daily, experiencing a second shedding phase but still seeing positive results. They seek advice from others who have experienced similar shedding.

Increased hair shedding after starting Dutasteride is normal and indicates treatment efficacy, as it triggers a synchronized shedding phase to make way for stronger hair growth. It is advised to continue with the current treatment plan and assess results in 9 to 12 months.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The user started using Minoxidil and finasteride for hair loss, noticing some progress after six months, despite a recent shedding phase. They also use derma stamping and various topical products, though their effectiveness is uncertain.

The user is experiencing significant hair loss after switching from finasteride to dutasteride for five months. Suggestions include that the hair loss might be a normal shedding phase, with some recommending continuing the treatment for up to 24 months or considering alternatives like RU58841.

The user is experiencing increased hair shedding and is concerned about regression despite consistent use of finasteride, minoxidil, and other treatments. The consensus is that this is likely a temporary shedding phase, and adjustments to the dermarolling frequency are suggested.

The user experienced significant hair improvement after 4 months of using 1.25mg finasteride daily and 5% Minoxidil foam. They reported no side effects and no noticeable shedding phase.

The user is experiencing worsening hair loss despite using finasteride and oral minoxidil, and is questioning if it's a shedding phase or if the treatments are ineffective. They express regret for starting the treatments as preventative maintenance.

The user is experiencing increased thinning around the crown after starting topical Minoxidil and is considering switching from Finasteride to Dutasteride. Responses suggest the thinning might be a temporary shedding phase due to the new treatment, and it's advised to continue the current regimen and monitor progress.

The user shared a 10-month hairline update using 5% topical Minoxidil and 2.5% oral Finasteride, noting some improvement despite a second shedding phase. They switched to oral Minoxidil for convenience, which may have caused the shedding.

A 30-year-old male experienced hair shedding while using Minoxidil and Finasteride, with concerns about whether this is a normal shedding phase. Despite drastic hair loss, he continues the treatment, hoping for regrowth, and receives advice to maintain the regimen and consider lifestyle changes.

A woman experiencing hormonal hair loss is on dutasteride and bicalutamide, which initially improved her hair, but she is now experiencing a second shedding phase with significant short hair loss. Despite normal hormone levels and no deficiencies, she is unsure if this shedding is normal and seeks advice.